Hong Kong Life Sciences and Technologies Group Limited

What Hong Kong Life Sciences and Technologies Group Limited does

Hong Kong Life Sciences and Technologies Group Limited is a Hong Kong-incorporated public limited company that self-describes as operating in the life sciences sector, with stated focus areas of anti-aging and stem cell technology and the marketing of life science products. The company was originally listed on the Hong Kong Stock Exchange under stock code 8085, but its listing was cancelled effective 9 September 2020, after which it underwent a capital reorganisation and adopted an amended and restated memorandum of association effective 17 November 2021 pursuant to shareholder resolutions passed at an extraordinary general meeting on 22 June 2021. Headquartered at Room 1305, 13/F, Loon Kee Building, 267-275 Des Voeux Road Central in Hong Kong, the entity currently reports a headcount of 1-10 employees.

The company's public-facing website operates exclusively as a corporate communications and investor-relations portal. It hosts audited financial statements through the year ended 31 March 2022, corporate announcements, circulars, and constitutional documents, but discloses no branded products, service offerings, technology stack, customer relationships, pricing, distribution channels, partnerships, or management team. No subsidiaries, funding rounds, patents, certifications, regulatory actions, or M&A activity are recorded in the available source material, and no proprietary technology architecture, AI/ML capabilities, or data assets are described.

From a business-model standpoint, the available evidence does not support a clear operating thesis: there are no disclosed revenue figures, customer counts, pricing models, or go-to-market channels. The combination of delisting, capital reorganisation, minimal headcount, absence of disclosed commercial activity, and a website limited to statutory filings is consistent with either a dormant or near-dormant investment holding entity rather than an operating biotech. Ownership and shareholder structure are not disclosed in the public sources reviewed.

Name

Hong Kong Life Sciences and Technologies Group Limited

Legal name

Hong Kong Life Sciences and Technologies Group Limited

Website

https://hklifesciences.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Hong Kong Life Sciences and Technologies Group Limited is a Hong Kong-incorporated, formerly listed entity that self-describes a focus on anti-aging and stem cell technology and life science product marketing, now operating as a near-dormant corporate shell following 2020 delisting and 2021 capital reorganisation, with no disclosed products, customers, or revenue.

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)

Keywords

• Anti-aging biotechnology
• Stem cell technology
• Life sciences marketing
• Biotech product marketing
• Health biotechnology

Headquarters

HQ city

Central

HQ country

Hong Kong SAR China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Others

Core offering

Hong Kong Life Sciences and Technologies Group Limited is a Hong Kong-based biotech firm that specializes in anti-aging and stem cell technology, and the marketing of life science products. The company maintains a corporate communications and investor relations presence through financial reporting and shareholder disclosures, with no distinct branded products or service offerings identified on the public-facing website.

Product overview

Hong Kong Life Sciences and Technologies Group Limited is a Hong Kong-listed investment holding company operating primarily in the life sciences and technologies sector. The company maintains investor relations presence through financial reporting, corporate announcements, and shareholder communications. Based on the available source material, no distinct product names, branded offerings, or technology modules were identified on the public-facing website. The website primarily serves as a corporate communications portal for financial disclosures and shareholder information rather than a product or service marketing platform.

Differentiator

Problem solved

Functional benefit

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves7 records

Direct peers

• Mesoblast: Mesoblast is a regenerative medicine company developing mesenchymal stem cell therapies for inflammatory and cardiovascular diseases. It is directly comparable to the company's claimed focus on stem cell technology.
• BrainStorm Cell Therapeutics: BrainStorm Cell Therapeutics develops autologous stem cell therapies for neurodegenerative diseases. It is a direct peer in the stem cell therapeutics space, though smaller and US-based rather than Hong Kong-based.
• Cellular Biomedicine Group: Cellular Biomedicine Group is a China-based cell therapy company developing stem cell and immune cell therapies, directly comparable in both therapeutic focus and Asia-Pacific geographic positioning.

Regional players

• Genscript: GenScript is a Hong Kong-listed life sciences services company offering gene synthesis, peptide, and cell therapy services, comparable as a Hong Kong-domiciled life sciences and biotech services player.
• Sino Biopharmaceutical: Sino Biopharmaceutical is a major Hong Kong-listed pharmaceutical holding group, broadly comparable as a life sciences holding company listed and headquartered in Hong Kong with a similar structural profile to the subject company.
• Junshi Biosciences: Junshi Biosciences is a Hong Kong-listed innovation-driven biotech company developing innovative therapeutics, comparable as a Hong Kong-listed life sciences company operating in the broader biotech sector.

Broad incumbents

• Lonza Group: Lonza Group is a global CDMO with significant cell and gene therapy manufacturing capabilities, broadly comparable as a much larger established life sciences technology and services company with cell therapy focus.
• WuXi AppTec: WuXi AppTec is the largest China-based CRO/CDMO serving global pharma and biotech clients, broadly comparable as a much larger Hong Kong-listed life sciences services and technology company.
• Pharmaron: Pharmaron is a major China-based CRO/CDMO providing drug discovery and development services, broadly comparable as a much larger life sciences services company operating in the Greater China ecosystem.
• BeiGene: BeiGene is a major commercial-stage global oncology biotech with significant Hong Kong and Nasdaq listings, broadly comparable as a much larger Hong Kong-domiciled life sciences company.

Market position

Strengths2 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hong Kong Life Sciences and Technologies Group Limited